Comparative Pharmacology
Head-to-head clinical analysis: SORINE versus SOTYLIZE.
Peer-Reviewed Evidence
Head-to-head clinical analysis: SORINE versus SOTYLIZE.
SORINE vs SOTYLIZE
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Selective beta-1 adrenergic receptor antagonist; decreases cardiac output, heart rate, and blood pressure.
Selective beta-1 adrenergic receptor antagonist; also exhibits class III antiarrhythmic activity (potassium channel blockade), prolonging cardiac repolarization and refractory periods.
5 mg orally once daily, increased after 4 weeks to 10 mg orally once daily if tolerated and needed.
Initial: 80 mg orally twice daily. May increase every 2-3 days in 40-80 mg increments up to 240-320 mg/day. Maximum: 320 mg/day in divided doses.
None Documented
None Documented
4-6 hours in healthy adults; prolonged to 12-18 hours in severe renal impairment (CrCl <30 mL/min).
Terminal elimination half-life is 12-16 hours in patients with normal renal function; can extend up to 30-40 hours in renal impairment, requiring dose adjustment.
Renal (80% unchanged) and biliary (15% as metabolites); 5% fecal.
Primarily renal excretion of unchanged drug; 85-90% eliminated unchanged in urine, with the remainder via feces (<5%) and minimal biliary excretion.
Category C
Category C
Antiarrhythmic
Antiarrhythmic